Zydus Cadila is currently trading at Rs. 339.90, up by 8.15 points or 2.46% from its previous closing of Rs. 331.75 on the BSE.

The scrip opened at Rs. 334.60 and has touched a high and low of Rs. 344.00 and Rs. 331.05 respectively. So far 329258 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 378.00 on 09-Apr-2020 and a 52 week low of Rs. 206.45 on 22-Aug-2019.

Last one week high and low of the scrip stood at Rs. 349.80 and Rs. 326.70 respectively. The current market cap of the company is Rs. 35017.12 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.20% and 7.80% respectively.

Zydus Cadila has declared that its biological therapy Pegylated Interferon alpha-2b, ‘PegiHep’ can emerge as one of the pathways to treat COVID 19. 

The treatment has emerged after the publication of two non-peer reviewed research articles at bioRxiv and medRxiv, the COVID-19 pre-print servers hosted by Cold Spring Harbor Laboratory. The first one by the University of Texas Medical Branch, Galveston, showed an evidence of a direct anti-viral effect of Interferon alpha against novel Coronavirus in vitro. The study demonstrated around 10,000 fold reduction in virus titre in cells that were pre-treated with Interferon alpha 48 hours earlier.

The second by a group of universities in China, Australia and Canada retrospectively analysed 77 moderate COVID-19 subjects in Wuhan and observed that those who received Interferon alpha-2b showed a significant reduction in the duration of virus shedding period and even in levels of the inflammatory cytokine, IL-6. This suggests that if a long-acting molecule like Pegylated Interferon alpha is given early on in the infection, the patient suffering from COVID 19 will have a significant benefit as the viral load is reduced, lesser IL-6 is produced and virus eliminating specific immune response is generated.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

917.80 3.95 (0.43%)
19-Dec-2025 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1747.50
Dr. Reddys Lab 1276.30
Cipla 1513.00
Zydus Lifesciences 917.80
Lupin 2125.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×